Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

PETHEMA Foundation: Clinical Trials & FDA Approval Profile

PETHEMA Foundation (Global / Institutional) sponsors 23 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (6 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)8.7%
Median Closed Enrollment vs National (145 pts)63 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for PETHEMA Foundation
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)23
Active Pipeline (Recruiting Now)16 (6)
Completed vs Stopped Early4 / 2 (8.7%)
Median Closed Actual Enrollment63 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With PETHEMA Foundation
Hospital Research SiteLocationShared Protocols
Hospital Universitario 12 de OctubreMadrid9
Hospital Universitario de SalamancaSalamanca7
Hospital Universitari i Politecnic La FeValencia7

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by PETHEMA Foundation
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07478991Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)Phase IIIRECRUITING
NCT05558319NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomidePhase IIIRECRUITING
NCT06544785Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPhase IIRECRUITING
NCT07507760Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsPhase IIRECRUITING
NCT04090736Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard ChemothePhase IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the PETHEMA Foundation Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI